单位:[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.肿瘤科华中科技大学同济医学院附属同济医院[2]Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China.[3]Department of PICC, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China护理部PICC华中科技大学同济医学院附属同济医院
第一作者单位:[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.[*1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei 430030, China.
推荐引用方式(GB/T 7714):
Zhu Sixian,Xu Huiting,Chen Runzhi,et al.DNA methylation and miR-92a-3p-mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway[J].JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2023,27(6):788-802.doi:10.1111/jcmm.17612.
APA:
Zhu Sixian,Xu Huiting,Chen Runzhi,Shen Qian,Yang Dongmei...&Fu Qiang.(2023).DNA methylation and miR-92a-3p-mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,27,(6)
MLA:
Zhu Sixian,et al."DNA methylation and miR-92a-3p-mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway".JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 27..6(2023):788-802